INM Stock - InMed Pharmaceuticals Inc.
Unlock GoAI Insights for INM
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $4.94M | $4.60M | $4.14M | $1.09M | N/A |
| Gross Profit | $1.71M | $1.10M | $1.40M | $543,546 | N/A |
| Gross Margin | 34.5% | 23.9% | 33.9% | 49.9% | N/A |
| Operating Income | $-7,917,995 | $-8,134,430 | $-8,378,787 | $-13,791,756 | $-12,171,142 |
| Net Income | $-8,162,133 | $-7,675,550 | $-7,947,622 | $-18,600,117 | $-12,649,279 |
| Net Margin | -165.1% | -166.9% | -192.2% | -1707.3% | N/A |
| EPS | $-11.44 | $-27.55 | $-86.00 | $-21350.51 | $-938.91 |
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosynthesis-based manufacturing approach, for synthesizing pharmaceutical-grade cannabinoids. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
Visit WebsiteEarnings History & Surprises
INMEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Feb 10, 2026 | — | — | — | — |
Q4 2025 | Nov 6, 2025 | — | $-0.44 | — | — |
Q3 2025 | Sep 23, 2025 | — | $-3.80 | — | — |
Q2 2025 | May 12, 2025 | — | $-1.94 | — | — |
Q1 2025 | Feb 12, 2025 | — | $-3.64 | — | — |
Q4 2024 | Nov 14, 2024 | — | $-54.20 | — | — |
Q3 2024 | Sep 27, 2024 | — | $-3.80 | — | — |
Q2 2024 | May 14, 2024 | — | $-3.60 | — | — |
Q1 2024 | Feb 13, 2024 | — | $-3.80 | — | — |
Q4 2023 | Nov 14, 2023 | — | $-15.20 | — | — |
Q3 2023 | Sep 29, 2023 | $-85.00 | $-12.92 | +84.8% | ✓ BEAT |
Q2 2023 | May 15, 2023 | $-90.00 | $-12.00 | +86.7% | ✓ BEAT |
Q1 2023 | Feb 17, 2023 | $-90.00 | $-18.20 | +79.8% | ✓ BEAT |
Q4 2022 | Nov 11, 2022 | $-85.00 | $-81.20 | +4.5% | ✓ BEAT |
Q3 2022 | Sep 23, 2022 | $-110.00 | $-258.40 | -134.9% | ✗ MISS |
Q2 2022 | May 13, 2022 | $-115.00 | $-125.00 | -8.7% | ✗ MISS |
Q1 2022 | Feb 14, 2022 | $-120.00 | $-155.00 | -29.2% | ✗ MISS |
Q4 2021 | Nov 10, 2021 | $-175.00 | $-125.00 | +28.6% | ✓ BEAT |
Q3 2021 | Sep 24, 2021 | $-170.00 | $-205.00 | -20.6% | ✗ MISS |
Latest News
InMed Pharmaceuticals Expects Negative Impact On BayMedica From New Act H.R. 5371; Says BayMedica Evaluating Alternative Supply Chain Options
📉 NegativeInMed Pharmaceuticals Has Received A Notice Of Allowance For A U.S. Patent Titled "CANNABINOID ANALOGS AND METHODS FOR THEIR PREPARATION (USEFUL FOR NEUROLOGICAL CONDITIONS, MOOD/BEHAVIOR DISORDERS, INFECTIONS, AND CANCERS)"
📈 PositiveFrequently Asked Questions about INM
What is INM's current stock price?
What is the analyst price target for INM?
What sector is InMed Pharmaceuticals Inc. in?
What is INM's market cap?
Does INM pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to INM for comparison